BUSINESS

Approval by January Unlikely for SanBio’s Lead Cell Therapy as Production Review Stalls

October 21, 2022
SanBio said on October 20 that the company is unlikely to obtain Japanese regulatory approval for its lead cell therapy SB623 during the current fiscal year ending January 2023, due to the longer-than-expected timeline for the production-related review. SB623 was…

To read the full story

Related Article

BUSINESS

By Shinya Sato

The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…

By Philip Carrigan

1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…

By Takashi Ebisawa

A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…